Want to see AU:4DX full AI Analyst Report?
Top Page
4DMedical Ltd
(Sydney:4DX)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$3.50
▼(-9.79% Downside)
Action:Reiterated
Date:09/19/26
The score is held back primarily by weak financial performance—large ongoing losses and persistent cash burn—despite strong revenue growth and a low-leverage balance sheet. Technicals are supportive with the stock trading above key moving averages and positive momentum, but valuation remains challenged due to negative earnings and no indicated dividend yield.
Positive Factors
Strong Revenue Growth
Rapid revenue expansion indicates that 4DMedical is increasing adoption of its respiratory imaging and lung-function software. If this trajectory persists, greater scale could improve operating leverage, broaden clinical use, and support a more durable commercial position over the next several quarters.
Negative Factors
Persistent Cash Burn
Continued negative operating and free cash flow means the business is not yet funding its operations internally. Even with improved 2026 cash-burn growth, ongoing cash consumption may require further financing and can constrain investment capacity if profitability takes longer to achieve.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid revenue expansion indicates that 4DMedical is increasing adoption of its respiratory imaging and lung-function software. If this trajectory persists, greater scale could improve operating leverage, broaden clinical use, and support a more durable commercial position over the next several quarters.
Read all positive factors
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.07B
Dividend YieldN/A
Average Volume (3M)3.61M
Price to Earnings (P/E)―
Beta (1Y)2.49
Revenue Growth20.64%
EPS Growth-457.40%
CountryAU
Employees181
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.39
Shares Outstanding602,238,500
10 Day Avg. Volume2,677,865
30 Day Avg. Volume3,607,128
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)181.41
Price to Sales (P/S)4371.54
P/FCF Ratio-957.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$5.05Price Target Upside30.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$22.27M
4DMedical Ltd Business Overview & Revenue Model
Company Description
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, a...
4DMedical Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.06M | 5.85M | 3.75M | 718.58K | 1.05M |
| Gross Profit | -38.08M | 5.39M | 3.52M | 684.43K | 280.62K |
| EBITDA | -52.00M | -42.83M | -31.86M | -33.74M | -35.25M |
| Net Income | -204.44M | -30.07M | -35.98M | -31.46M | -24.59M |
Balance Sheet | |||||
| Total Assets | 365.34M | 94.81M | 120.02M | 92.92M | 74.31M |
| Cash, Cash Equivalents and Short-Term Investments | 277.95M | 6.88M | 30.61M | 69.58M | 51.11M |
| Total Debt | 3.22M | 4.31M | 5.12M | 5.14M | 6.24M |
| Total Liabilities | 195.17M | 30.58M | 49.09M | 21.46M | 14.80M |
| Stockholders Equity | 170.16M | 64.24M | 70.93M | 71.46M | 59.51M |
Cash Flow | |||||
| Free Cash Flow | -32.22M | -34.56M | -31.17M | -23.38M | -28.35M |
| Operating Cash Flow | -31.27M | -34.48M | -30.87M | -22.65M | -25.27M |
| Investing Cash Flow | -2.43M | -1.62M | -40.04M | -1.61M | -3.50M |
| Financing Cash Flow | 304.78M | 12.37M | 31.94M | 42.73M | -995.47K |
4DMedical Ltd Technical Analysis
Negative
3.88
Price Trends
3.82
Negative
3.89
Negative
4.10
Negative
Market Momentum
-0.09
Positive
37.07
Neutral
7.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:4DX, the sentiment is Negative. The current price of 3.88 is below the 20-day moving average (MA) of 3.94, above the 50-day MA of 3.82, and below the 200-day MA of 4.10, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 37.07 is Neutral, neither overbought nor oversold. The STOCH value of 7.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:4DX.
4DMedical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$49.83B | 23.96 | 23.88% | 1.04% | 4.74% | 4.44% | |
57 Neutral | AU$45.95M | 209.09 | 0.93% | ― | 18.54% | ― | |
55 Neutral | AU$2.07B | -8.70 | -288.42% | ― | 20.64% | -457.40% | |
55 Neutral | AU$65.93M | -24.79 | -5.44% | ― | 2.73% | 25.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$139.43M | -16.54 | -46.84% | ― | ― | 20.40% | |
41 Neutral | AU$46.52M | -2.38 | -62.14% | 0.64% | 12.05% | -31.71% |
* Healthcare Sector Average
AU:4DX
4DMedical Ltd
3.43
1.60
87.43%
AU:CMP
Compumedics Limited
0.23
-0.11
-31.34%
AU:SOM
Somnomed Limited
0.30
-0.56
-65.12%
AU:CYC
Cyclopharm Limited
0.37
-0.27
-42.19%
AU:EMV
EMvision Medical Devices Ltd.
1.50
-0.26
-14.77%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
35.13
-3.55
-9.17%
4DMedical Ltd Corporate Events
4DMedical racks up record scan volumes as global lung imaging footprint expands
Oct 27, 2026
4DMedical reported a strong quarter marked by significant commercial traction for its respiratory imaging platform across key international markets. The company secured a long-term contract for its LDAi™ technology to detect COPD in a major ...
4DMedical flags global growth, CT:VQ momentum and leadership shake-up at 2026 AGM
Oct 27, 2026
4DMedical Limited used its 2026 Annual General Meeting to highlight a transformational year in which it consolidated its status as a growing leader in respiratory imaging and diagnostics. The company reported operating revenue of $7.1 million, up ...
4DMedical Adjusts Capital Structure as 5,000 Performance Rights Lapse
Oct 2, 2026
4DMedical Ltd has notified the ASX of the lapse of 5,000 performance rights, designated under the code 4DXAX, after the conditional rights became incapable of being satisfied. The cessation, effective 29 October 2026, reflects an adjustment to the...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Oct 2, 2026
4DMedical Ltd has applied for the quotation of 440,313 new ordinary fully paid shares on the ASX, to be issued under the code 4DX. The securities were issued on 25 September 2026 and the company lodged the application as a new announcement dated 2...
4DMedical Sets Hybrid AGM for October 2026
Sep 24, 2026
4DMedical Limited has announced that its Annual General Meeting will take place on 28 October 2026 at 10:00am AEDT as a hybrid event, allowing shareholders to participate either in person in Melbourne or online via a dedicated meeting platform. Th...
4DMedical Files Updated Corporate Governance Statement with ASX
Sep 24, 2026
4DMedical Limited has lodged its corporate governance statement for the year ended 30 June 2026, confirming that the document is current as of 24 September 2026 and available on the company’s website. The filing, made in accordance with ASX ...
4DMedical reshapes board and leadership to drive next growth phase
Sep 23, 2026
4DMedical has announced a significant board transition and senior leadership reshuffle as it prepares for its next phase of commercial growth in respiratory imaging. Long-serving chair Lil Bianchi will retire at the conclusion of the 2026 AGM, wit...
JPMorgan Ceases to Be Substantial Holder in 4DMedical
Sep 22, 2026
JPMorgan Chase Co and its affiliates have disclosed that they have ceased to be a substantial holder in 4DMedical Ltd as of 18 September 2026, following a series of transactions and securities lending-related movements involving ordinary shares. ...
4DMedical Lists Additional Ordinary Shares Following Option Conversions
Sep 18, 2026
4DMedical Ltd has applied for quotation on the ASX of 19,445 new fully paid ordinary shares, issued on 11 September 2026 following the exercise or conversion of existing options or other convertible securities. The additional shares modestly expan...
4DMedical Issues New Shares Under Long-Term Incentive Plan
Sep 4, 2026
4DMedical Limited has issued 1,626,496 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan. The issuance, conducted without a prospectus under Australian Corporations Act provisions, reflects ongoing imp...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Sep 4, 2026
4DMedical Ltd has applied for quotation of additional ordinary fully paid shares on the ASX, seeking to list a total of 1,638,302 new securities. The new shares were issued on August 28 and September 4, 2026, primarily resulting from the exercise ...
4DMedical Sets October 2026 AGM and Board Elections
Aug 28, 2026
4DMedical Ltd, a global medical technology company, specializes in advanced respiratory imaging and AI-driven software that convert routine lung scans into detailed functional analyses. Through a SaaS delivery model, its FDA-cleared XV LVAS, CT LV...
4DMedical lifts SaaS revenue and margins but books large non-cash loss
Aug 28, 2026
4DMedical reported a 21% rise in operating revenue to A$7.1 million for the year to 30 June 2026, with gross margins above 90%, underpinned by a 23% increase in underlying SaaS revenue from hospitals, radiology partners, AI distributors and global...
4DMedical Expands ASX-Quoted Share Base Through Option Conversions
Aug 14, 2026
4DMedical Ltd has lodged an application with the ASX for quotation of additional ordinary fully paid shares under its 4DX ticker. The newly quoted securities arise from the exercise or conversion of existing options or other convertible instrument...
4DMedical Seeks ASX Quotation for 33,406 New Ordinary Shares
Aug 13, 2026
4DMedical Ltd has applied to the ASX for quotation of 33,406 new fully paid ordinary shares under its 4DX code, with an issue date of 13 August 2026. The modest share issuance, arising from previously announced transactions, marginally expands the...
4DMedical accelerates global rollout of CT:VQ™ as revenue and scan volumes surge
Jul 31, 2026
4DMedical reported a solid quarter with FY26 operating revenue rising 23% to $7.2 million, supported by a 43% jump in quarterly scan volumes and gross margins above 90%. The company ended June with $278 million in cash and is now delivering its lu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.